Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02416466 · ClinicalTrials.gov registry record · Phase 1
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
A Phase 1 study of Liver Metastases, sponsored by Roger Williams Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02416466 is a Phase 1 study of Liver Metastases that has completed, run by Roger Williams Medical Center. The registered enrollment target is 8 participants, below the 68-participant average among 27 other Liver Metastases trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02416466, a Phase 1 study of Liver Metastases, has completed, sponsored by Roger Williams Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label fixed dose phase Ib of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases.
Conditions Studied
Interventions
- BIOLOGICAL anti-CEA CAR-T cells
- DEVICE Sir-Spheres
Study Locations (1)
Rhode Island
- Roger Williams Medical Center - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02416466
The ClinicalTrials.gov registry entry for NCT02416466 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 27 other Liver Metastases trials with a reported enrollment target (88% lower). The listed sponsor is Roger Williams Medical Center, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Metastases appearing as the primary indexed condition, and to 2 interventions - of which anti-CEA CAR-T cells is the first listed.
NCT02416466 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT02416466 about?
NCT02416466 is a clinical study titled "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases". This is an open label fixed dose phase Ib of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases.
What is the current status of trial NCT02416466?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-04. Estimated completion is 2018-06.
What conditions does trial NCT02416466 study?
This clinical trial studies the following conditions: Liver Metastases.
What interventions are being tested in trial NCT02416466?
The interventions under investigation include: anti-CEA CAR-T cells (BIOLOGICAL), Sir-Spheres (DEVICE).
Who is sponsoring clinical trial NCT02416466?
This trial is sponsored by Roger Williams Medical Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02416466 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
RECRUITING · Phase 1
-
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
-
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
COMPLETED · Phase 1
-
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
COMPLETED · Phase 1
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.